Issue 7, 2018

Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway

Abstract

The successful delivery of toxic cargo directly to tumor cells is of primary importance in targeted (α) particle therapy. Complexes of radioactive atoms with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelating agent are considered as effective materials for such delivery processes. The DOTA chelator displays high affinity to radioactive metal isotopes and retains this capability after conjugation to tumor targeting moieties. Although the α-decay chains are well defined for many isotopes, the stability of chelations during the decay process and the impact of released energy on their structures remain unknown. The radioactive isotope 225Ac is an α-particle emitter that can be easily chelated by DOTA. However, 225Ac has a complex decay chain with four α-particle emissions during decay of each radionuclide. To advance our fundamental understanding of the consequences of α-decay on the stability of tumor-targeted 225Ac–DOTA conjugate radiopharmaceuticals, we performed first principles calculations of the structure, stability, and electronic properties of the DOTA chelator to the 225Ac radioactive isotope, and the initial daughters in the decay chain, 225Ac, 221Fr, 217At and 213Bi. Our calculations show that the atomic positions, binding energies, and electron localization functions are affected by the interplay between spin–orbit coupling, weak dispersive interactions, and environmental factors. Future empirical measurements may be guided and interpreted in light of these results.

Graphical abstract: Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway

Article information

Article type
Research Article
Submitted
28 Mar 2018
Accepted
05 Jun 2018
First published
06 Jun 2018

Med. Chem. Commun., 2018,9, 1155-1163

Author version available

Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway

A. R. Khabibullin, A. Karolak, M. M. Budzevich, M. L. McLaughlin, D. L. Morse and L. M. Woods, Med. Chem. Commun., 2018, 9, 1155 DOI: 10.1039/C8MD00170G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements